A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer

Conditions

• Relapsed/Refractory Small Cell Lung Cancer

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• BMS-986525 — DRUG
  Specified dose on specified days
• Nivolumab — DRUG
  Specified dose on specified days

Study Details

The purpose of this study is to assess the safety and tolerability of BMS-986525 alone and in combination with Nivolumab in participants with Relapsed/Refractory Small Cell Lung Cancer

Key Dates

Start date

Feb 3, 2026

Status verified

May 2026

Primary completion

Apr 23, 2029

Completion

Apr 24, 2029

Study Design

Enrollment

240 participants (estimated)

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Part 1A: BMS-986525 Monotherapy Dose Escalation
• Experimental: Part 1B: BMS-986525 Combination with Nivolumab Dose Escalation
• Experimental: Part 2A: BMS-986525 Monotherapy Dose Expansion
• Experimental: Part 2B: BMS-986525 Combination with Nivolumab Dose Expansion

Primary Outcome Measure

Number of participants with adverse events (AEs) [ Time Frame: Up to approximately 2 years ]

Central Contacts

• BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
  855-907-3286
  [email protected]
• First line of the email MUST contain NCT # and Site #.

Locations (5)

Find similar trials in Detroit, MI